rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CAPR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick

      Regenxbio (RGNX) stock and Capricor Therapeutics (CAPR) stock rise as the White House pulls President Trump's pick to lead the FDA. Read more here.

      14h agoSeeking AlphaCAPRRGNX
      Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel - Capricor Therapeutics (NAS
      14h agoBenzingaCAPR
      CAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This Month
      20h agoYahoo FinanceCAPR
      ‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel
      Nov 17Yahoo FinanceCAPR
      Capricor Stock Rises: What's Going On?
      Nov 17BenzingaCAPR
      FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
      Nov 16Yahoo FinanceCAPRSVRA
      Capricor Therapeutics: A Close Look Before The November 22 DMD Drug Decision

      Capricor Therapeutics’ FDA decision date for its resubmitted DMD application shifts from Aug. 22 to Nov. Click here to read an analysis of CAPR stock now.

      Nov 12Seeking AlphaCAPR
      Capricor stock jumps as JonesTrading upgrades (CAPR:NASDAQ)

      Capricor Therapeutics (CAPR) stock gained after JonesTrading upgrades the biopharma ahead of a potential U.S. nod for its lead asset, Deramiocel. Read more here.

      Nov 11Seeking AlphaCAPR
      CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month
      Nov 11Yahoo FinanceCAPR
      Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
      Nov 11BenzingaCAPR
      Capricor Stock: The FDA's Objections Change My June Buy To A Sell (NASDAQ:CAPR)

      Capricor is rated Sell. FDA concerns put deramiocel approval odds at 10%-15%, with a new trial likely and over 50% downside. See more on CAPR here.

      Nov 11Seeking AlphaCAPR
      Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...

      Capricor Therapeutics Inc (CAPR) reported no Q3 2026 revenue but ended the quarter with approximately $198.5 million in cash and securities as it awaits a November 22, 2026 PDUFA date for Deramiocel.

      Nov 11Yahoo FinanceCAPR
      Capricor Therapeutics shares rise as FDA decision nears (CAPR:NASDAQ)
      Nov 11Seeking AlphaCAPR
      CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review
      Nov 10Yahoo FinanceCAPR
      Capricor Therapeutics Q3 2026 Earnings Call Transcript
      Nov 10BenzingaCAPR
      Capricor: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceCAPR
      Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 10Yahoo FinanceCAPR
      CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
      Nov 3Yahoo FinanceCAPR
      Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
      Nov 3Yahoo FinanceCAPR
      FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight
      Nov 2Yahoo FinanceALNYCAPRREGN
      CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring
      Nov 2Yahoo FinanceCAPR
      CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
      Oct 21Yahoo FinanceCAPR
      Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow (NASDAQ:CAPR) 2026-10-13
      Oct 13Seeking AlphaCAPR
      Oppenheimer reiterates Capricor stock rating on FDA data robustness
      Oct 8Investing.comCAPR
      CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
      Oct 7Yahoo FinanceCAPR
      Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

      Capricor Therapeutics (NASDAQ:CAPR) presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration. Company

      Oct 7Yahoo FinanceCAPR
      What's Going On With Capricor Therapeutics Stock Monday? - Capricor Therapeutics (NASDAQ:CAPR)

      Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.

      Oct 5BenzingaCAPR
      Capricor drops as deramiocel OLE data fails to quell regulatory concerns

      Capricor falls 10% despite positive deramiocel HOPE-3 OLE data for DMD. Read more here.

      Oct 5Seeking AlphaCAPR
      Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November

      Capricor’s Phase 3 HOPE-3 open-label extension data shows significant improvement in upper limb decline, but H.C. Wainwright said it did not remove the statistical uncertainty from the original trial.

      Oct 5Yahoo FinanceCAPR
      Capricor reports 24-month data for Duchenne therapy deramiocel
      Oct 5Investing.comCAPR
      Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

      -24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ca

      Oct 5Yahoo FinanceCAPR
      Capricor Therapeutics Stock Surges: What's Going On? - Capricor Therapeutics (NASDAQ:CAPR)

      Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.

      Sep 30BenzingaCAPR
      Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)

      Capricor (CAPR) spikes on new deramiocel HOPE-3 24-month Duchenne data ahead of Nov.

      Sep 30Seeking AlphaCAPR
      Why Did CAPR Stock Jump 20% After-Hours Today?
      Sep 30Yahoo FinanceCAPR
      Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - Lead Plaintiff Deadline is September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCAPR
      Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCAPR
      SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR
      Sep 24MorningstarCAPR
      CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
      Sep 23MorningstarCAPR
      Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions

      Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...

      Sep 23Yahoo FinanceCAPR
      Kaplan Fox Continues to Alert Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Class Action Deadline on September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailCAPR
      Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailCAPR
      Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 21The Globe and MailCAPR
      Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
      Sep 19MorningstarCAPR
      Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailCAPR
      Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
      Sep 18MorningstarCAPR
      Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
      Sep 18MorningstarCAPR
      Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026

      Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailCAPR
      Oppenheimer reiterates Capricor stock rating ahead of trial data
      Sep 17Investing.comCAPR
      Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

      – Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan

      Sep 17Yahoo FinanceCAPR
      Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026

      Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailCAPR

      This is the newest page. Registered accounts read further back.